<DOC>
	<DOCNO>NCT00213980</DOCNO>
	<brief_summary>This two arm , double-blind randomize study look effect zoledronate , bisphosphonate , bone mineral density ( BMD ) postmenopausal woman breast cancer .</brief_summary>
	<brief_title>Bone Mineral Density Effects Zoledronate Postmenopausal Women With Breast Cancer</brief_title>
	<detailed_description>This two arm , double-blind randomize study look effect zoledronate , bisphosphonate , bone mineral density ( BMD ) postmenopausal woman breast cancer . An approved bisphosphonate , alendronate , benefit patient osteoporosis , however , agent roughly 30 % incidence gastrointestinal symptom 50 % patient may take drug improperly , compromise absorption potentially efficacy . Zoledronate heterocyclic imidazole third generation bisphosphonate , administer intravenously ( IV ) little toxicity . Zoledronate potent alendronate , route administration problem poor oral bioavailability non-compliance .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Zoledronic acid</mesh_term>
	<mesh_term>Diphosphonates</mesh_term>
	<criteria>Postmenopausal woman , Stage III axillary node positive Currently disease free breast cancer invasive malignancy time registration No concurrent use bisphosphonates Metastatic disease</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2013</verification_date>
	<keyword>bone mineral density</keyword>
	<keyword>postmenopausal woman</keyword>
</DOC>